Structural Basis of Protein Kinase C Activation by Tumor Promoters (original) (raw)

Protein Kinase C: An Attractive Target for Cancer Therapy

Roberta Ricciarelli, Barbara Marengo

2011

View PDFchevron_right

Protein kinase C inhibitors as novel anticancer drugs

Peter Goekjian

Expert Opinion on Investigational Drugs, 2001

View PDFchevron_right

Rapid screening method for inhibitors of protein kinase C

Hiroyuki Osada

The Journal of Antibiotics, 1988

View PDFchevron_right

Structural analogies between protein kinase C activators

Véronique Cabiaux

Biochemical and Biophysical Research Communications, 1985

View PDFchevron_right

Tumor promotion by depleting cells of protein kinase C delta

Shigeo Ohno

Molecular and cellular biology, 1997

View PDFchevron_right

Efficacy of natural inhibitors against pkc: an in silico approach to combat cancer

Farrukh Jamal

View PDFchevron_right

Regulation and role of the atypical pkc isoforms in cell survival during tumor transformation

M. Diaz-Meco

Advances in Enzyme Regulation, 2001

View PDFchevron_right

Fine Tuning of Protein Kinase C (PKC) Isoforms in Cancer: Shortening the Distance from the Laboratory to the Bedside

Mini-Reviews in Medicinal Chemistry MRMC

Bentham science

View PDFchevron_right

Analysis of the phorbol ester pharmacophore on protein kinase C as a guide to the rational design of new classes of analogs

Konrad Koehler

Proceedings of the National Academy of Sciences, 1986

View PDFchevron_right

Equivocal, explicit and emergent actions of PKC isoforms in cancer

Peter Parker

Nature Reviews Cancer, 2020

View PDFchevron_right

Protein Kinase C as a Therapeutic Target

Beverly Teicher

Clinical Cancer Research, 2006

View PDFchevron_right

The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients

Alejandro Urtreger

Current Pharmaceutical Biotechnology, 2011

View PDFchevron_right

Comparison of Effects of Bryostatins 1 and 2 and 12-O-Tetradecanoylphorbol-13-acetate on Protein Kinase C Activity in A549 Human Lung Carcinoma Cells

Ian Dale

Cancer Research, 1989

View PDFchevron_right

Spontaneous occurrence of an inhibitor of protein kinase C localization in a thyroid cancer cell line: role in thyroid tumorigenesis

Deborah Schechtman

Advances in Enzyme Regulation, 2001

View PDFchevron_right

Protein kinase C desensitization by phorbol esters and its impact on growth of human breast cancer cells

Romano Regazzi

Biochemical and Biophysical Research Communications, 1986

View PDFchevron_right

Down-regulation of protein kinase C activity in 1,2-dimethylhydrazine-induced rat colonic tumors

R. Wali

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1991

View PDFchevron_right

The Transition from a Pharmacophore-Guided Approach to a Receptor-Guided Approach in the Design of Potent Protein Kinase C Ligands

Kassoum Nacro

Pharmacology & Therapeutics, 1999

View PDFchevron_right

Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C

Helmut Mett

Bioorganic & Medicinal Chemistry Letters, 1994

View PDFchevron_right

Structural investigation of protein kinase C inhibitors

Dov Barak

Journal of Molecular Structure-theochem, 1991

View PDFchevron_right

SupportedSpecificity , and Correlation with Drug Cytotoxicity 1 of Protein Kinase C : Structural Requirements , Isoform-Benzyladriamycin-14-valerate with the C 1-Regulatory Domain N Interaction of the Novel Anthracycline Antitumor Agent

Leonard Lothstein

2014

View PDFchevron_right

Structural and functional diversities of a family of signal transducing protein kinases, protein kinase C family; two distinct classes of PKC, conventional cPKC and novel nPKC

Shigeo Ohno

Advances in Enzyme Regulation, 1991

View PDFchevron_right

Protein kinase C - a question of specificity

Peter Parker

Trends in Biochemical Sciences, 1994

View PDFchevron_right

Inhibition of protein kinase C arrests proliferation of human tumors

Vicente Felipo

FEBS Letters, 1991

View PDFchevron_right

PKC-δ inhibits anchorage-dependent and -independent growth, enhances differentiation, and increases apoptosis in CaCo-2 cells

sharad khare

Gastroenterology, 2001

View PDFchevron_right

Tumor Promotion by Depleting Cells of Protein Kinase Cd

Armand Hornia

1997

View PDFchevron_right

Differential selectivity of ligands for the C1a and C1b phorbol ester binding domains of protein kinase Cdelta: possible correlation with tumor-promoting activity

Gerhardt Wagner

Cancer research, 1998

View PDFchevron_right

Protein kinase C α and δ are members of a large kinase family of high potential for novel anticancer targeted therapy

F. Lokiec

Targeted Oncology, 2006

View PDFchevron_right

Exploitation of protein kinase C: A useful target for cancer therapy

Philip Philip

Cancer Treatment Reviews, 2009

View PDFchevron_right

Inhibition of rodent protein kinase C by the anticarcinoma agent dequalinium

Lan Bo Chen

Cancer research, 1990

View PDFchevron_right

Differential Localization of Protein Kinase C δ by Phorbol Esters and Related Compounds Using a Fusion Protein with Green Fluorescent Protein

Kassoum Nacro

Journal of Biological Chemistry, 1999

View PDFchevron_right

Cancer-Associated Protein Kinase C Mutations Reveal Kinase’s Role as Tumor Suppressor

Frank Furnari, Tony Hunter

Cell, 2015

View PDFchevron_right

Domain interactions in protein kinase C

Peter Parker

2000

View PDFchevron_right

A comparative study of the effect of the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine and some homologous compounds on PKCα and PKCɛ

Pablo Conesa Zamora

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2005

View PDFchevron_right

Evaluation of (2S,4S)/(2R,4R) and (2S,4R)/(2R,4S) 6,6-N,N-dimethyl-2-methyl-2-oxo-1,3-dioxa-4-hexadecyl-6,aza-2-phosphacyclooctane bromide as inhibitors for protein kinase C, carnitine octanoyltransferase, and carnitine palmitoyltransferase

Rona Ramsay

Bioorganic & Medicinal Chemistry Letters, 1994

View PDFchevron_right

Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity, and correlation with drug cytotoxicity

Leonard Lothstein

Molecular cancer therapeutics, 2002

View PDFchevron_right